Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India

Goyal, Mohit; Patil, Pravin O.; Pathak, Himanshu; Santhanam, Sham; Goel, Anshul; Sharma, Vishnu M; Pandey, Akhilesh Kumar; Gupta, Nikhil; Jain, Rahul; Akerkar, Shashank M; Das, Parthajit; Dudam, Rajkiran; Mendiratta, Naval; Pandey, Bimlesh Dhar; Cb, Mithun; Singh, Bharat; Kumar, Sharath; Nolkha, Nilesh; Jain, Shriyanka; Jain, Somya; Sharma, Ashish; Misra, Durga Prasanna

doi:10.1136/annrheumdis-2020-218013

Cited by 18 publications

(18 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the COVID‐19 pandemic, studies in Asia showed that only 0.1%‐0.2% of SLE patients had documented infection with COVID‐19 85‐89 (Table 5). Together with other case series and reports, there is a total of 18 reported SLE patients with COVID‐19 infection 90‐94 .…”

Section: Resultsmentioning

confidence: 99%

Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements

et al. 2021

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a more common autoimmune rheumatic disease in the Asia‐Pacific region. The prognosis of SLE remains unsatisfactory in some Asian countries because of delayed diagnosis, limited access to medications, increased complications and issues of tolerability and adherence to treatment. The Asia‐Pacific League of Associations for Rheumatology SLE special interest group has recently published a set of consensus recommendations on the management of SLE for specialists, family physicians, specialty nurses, and other healthcare professionals in the Asia‐Pacific region. This article reports a systematic literature review of the infective complications of SLE in Asia and evidence for prevention of these infections by pre‐emptive antimicrobial therapy and vaccination.

show abstract

Section: Resultsmentioning

confidence: 99%

Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements

et al. 2021

View full text Add to dashboard Cite

show abstract

“…All of our patients had RA. On the other hand, a previous Indian report cited one case of COVID-19 among 845 patients with lupus [12]. However, among this cohort 17 had suspect symptoms, among which only two were tested.…”

Section: Discussionmentioning

confidence: 86%

COVID-19 in rheumatic diseases: A random cross-sectional telephonic survey

Goswami

Kumar

Kanjilal

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective. To describe the incidence, clinical course, and predictive factors of coronavirus 2019 (COVID-19) infection in a cohort of rheumatological patients residing in New Delhi (National Capital Region), India. Methods. We performed a cross-sectional, random telephonic survey from 20th April to 20th July 2020 on patients with rheumatic diseases. Patients were interviewed with a predesigned questionnaire. The incidence of COVID‐19 in the general population was obtained from open access government data repository. Report of reverse transcriptase polymerase chain reaction report was taken as confirmatory of COVID-19 infection. Results. Among the 900 contacted patients 840 responded (713 with rheumatoid arthritis (RA), 100 with systemic lupus erythematosus (SLE), 20 with spondylarthritis (SpA) and 7 with others; mean age 45 years, mean duration 11.3 years; 86% female). Among them 29 reported flu-like symptoms and four RA patients had confirmed COVID-19 infection. All of them were hospitalized with uneventful recovery. Rheumatological drugs were discontinued during the infectious episode. Disease modifying agents and biologics were equally received by those with or without COVID-19. The incidence of COVID-19 was similar to general Delhi population (0.476% vs 0.519% respectively, p=0.86). Two patients had relapse of rheumatic disease after recovery. After recovery from COVID-19 or Flu-like illness, eight patients (27.6%, 95% confidence interval 14.7-45.7) reported disease flare. Conclusion. Patients with rheumatic diseases in India have similar incidence of COVID-19 infection compared to the community. Relapse of underlying rheumatic disease after recovery is not uncommon and continuation of glucocorticoid through the infection should be considered.

show abstract

“…8 Another multicentric survey from our country included 845 patients of SLE and reported only two cases of COVID-19. 18 The COVID-19 Global Rheumatology Alliance had reported 600 cases of COVID-19 in patients with underlying rheumatological disorders. Of these 600 patients, 85 (14%) had underlying SLE.…”

Section: Discussionmentioning

confidence: 99%

Impact of the COVID-19 pandemic on patients with systemic lupus erythematosus: Observations from an Indian inception cohort

Rathi

Singh

et al. 2020

Lupus

View full text Add to dashboard Cite

Introduction The ongoing pandemic of COVID-19 has led to severe disruption of healthcare services worldwide. We conducted this study to assess the impact of COVID-19 pandemic on the management of Systemic Lupus Erythematosus (SLE) patients who were enrolled in the nation-wide inception cohort. Methods A questionnaire was administered to the SLE patients enrolled in the inception cohort. Questions related to the effect on disease activity, preventive measures adopted against COVID-19, the incidence of COVID-19, hardships faced in getting access to health care professionals and availability of medicines, adherence, fear of COVID-19 and the potential benefits of being part of the registry. Results A total of 1040 (90% females) patients completed the questionnaire. The mean age was 27.5 ± 19.1 years and the mean disease duration was 1.25 years. Twenty-Four (2.3%) patients had developed fever (>1 day) during this period, including one patient with additional symptoms of diarrhoea and anosmia, however, none of the patients developed COVID-19 infection. 262 patients (25.2%) reported financial difficulty during this period and patients reported an average excess expenditure of at least 2255.45 INR ($30) per month. 378 patients (36%) reported problems in getting their prescribed medicines due to lockdown. Of these, 167 (40%) patients needed to change their medication schedule due to this non-availability. Almost 54% of patients missed their scheduled follow up visits during the lockdown period and 37% of patients were unable to get their investigations done due to closure of laboratories and hospitals. 266 patients (25.5%) reported worsening of various symptoms of SLE during this period. Almost 61% patients felt confident that being associated with the inception cohort had helped them in managing their disease better during this period of lockdown as they received help in the form of timely and frequent telephonic consults, assistance in making the medicines available, and regular counselling resulting in abetment of their fears and anxieties. Conclusion The current COVID-19 pandemic has made a huge impact on our SLE patients. Patients faced difficulty in the availability of medicines, missed the doses of medicines, had financial constraints, and spent more money on health during the pandemic.

show abstract

Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India

Abstract: Table 1 Demographics and clinical characteristics of patients with SLE with confirmed or suspected COVID-19 COVID-19-like clinical picture (group A)* Contact with patient with COVID-19 (group B)*

Cited by 18 publications

References 4 publications

Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements

Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements

COVID-19 in rheumatic diseases: A random cross-sectional telephonic survey

Impact of the COVID-19 pandemic on patients with systemic lupus erythematosus: Observations from an Indian inception cohort

Contact Info

Product

Resources

About